{
    "2019-02-14": [
        [
            {
                "time": "2023-10-05",
                "original_text": "Bayer stresses drug's tolerability in bid for prostate cancer market",
                "features": {
                    "keywords": [
                        "Bayer",
                        "drug",
                        "prostate cancer",
                        "market"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "The Daily Biotech Pulse: Vanda Q4 Results, Inovio Debt Offering, Caladrius Diabetes Drug Flunks Mid-Stage Trial",
                "features": {
                    "keywords": [
                        "Vanda",
                        "Q4 Results",
                        "Inovio",
                        "Debt Offering",
                        "Caladrius",
                        "Diabetes Drug",
                        "Mid-Stage Trial"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Pfizer still holds the lead in the erectile dysfunction market even as Viagra sales falter",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "erectile dysfunction",
                        "Viagra",
                        "sales"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}